Acumen Pharmaceuticals, Inc.
ABOS
$2.48
-$0.09-3.50%
NASDAQ
Corporate Info
Website
Phone Number
617 344 4190
Address
1210-1220 Washington St.
Suite 210
Newton, MA 02465
Suite 210
Newton, MA 02465
Country
United States
Year Founded
1996
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
Business Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer’s disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.